Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 13;19(2):475–487. doi: 10.1111/ajt.14970

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

(A) Clinical course of the 2 tolerant patients transplanted at our center (pat. N18 and N19). Both patients underwent transplantation with only a short steroid taper to reduce ischemia‐reperfusion injury. No further immunosuppression was administered. (B) Humoral immune activation was assessed by measuring donor‐ and recipient‐specific antibodies. There were no signs of humoral immune activation. (C) Chimerism was assessed via real‐time PCR in separated T cells before and 1 year after RT in both patients. The proportion of recipient‐derived T cells was low and virtually didn't change over the time. (D) Protocol biopsies performed 1 month and 12 months after RT showed structurally regular renal tissue with no signs of cell‐ or antibody‐mediated rejection. Data from patient N18 have been shown previously (Schwarz 2016) with a shorter follow‐up19 [Color figure can be viewed at wileyonlinelibrary.com]